Clinical Trial

Investigation of the Anti-inflammatory Effect of Ketamine in Cardiac Surgery

Completed Phase 4
View on ClinicalTrials.gov →
Summary
Background: The inflammatory response following cardiac surgery is known to contribute significantly to morbidity and mortality. Neutrophils and inflammatory mediators play a critical role in the pathogenesis of postoperative complications. The aim of this study was to evaluate the effect of intraoperative ketamine administration on the inflammatory response in patients undergoing cardiac surgery using routinely employed immuno-inflammatory parameters in clinical practice. Methods: After randomization, patients were divided into two groups: the ketamine group and the control group. Following admission to the operating room, standard monitoring and anesthesia induction were performed. In addition to the control group, patients in the ketamine group received 1 mg/kg ketamine during induction and a continuous intravenous infusion of 2.4 mg/kg/h ketamine for maintenance. Immuno-inflammatory parameters were assessed using routine blood tests obtained preoperatively and on postoperative day 1. These parameters included leukocyte, neutrophil, lymphocyte, and platelet counts; neutrophil-to-lymphocyte ratio (NLR); platelet-to-lymphocyte ratio (PLR); NLR index; delta NLR; ΔPLR; PLR index; systemic inflammatory response index (SIRI); systemic immune-inflammation index (SII); and C-reactive protein (CRP), ΔCRP, and CRP index. In addition, patients' pain scores within the first 24 hours following postoperative extubation, as well as hospital mortality and morbidity rates, were evaluated.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-15; most recent amendment 2026-04-22.
Trial Details
NCT Number NCT07536633
Lead Sponsor Konya City Hospital
Conditions Cardiac Surgery
Enrollment 177 participants
Start Date 2022-10-30
Primary Completion 2023-03-30 (estimated)
Study Completion 2023-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-27